Status:
RECRUITING
Coenzyme Q10 for Gulf War Illness: A Replication Study
Lead Sponsor:
University of California, San Diego
Collaborating Sponsors:
United States Department of Defense
Conditions:
Gulf War Syndrome
Persian Gulf Syndrome
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
Eligibility Criteria
Inclusion
- Meets both CDC and Kansas deployment and symptom inclusion criteria.
- Does not have a disqualifying condition.
- Able to travel to a local Quest facility for study blood draws.
- Adequate internet access to allow ZoomPro visit participation and remote survey completion.
- Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).
- Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.
Exclusion
- Participating in another clinical trial.
- Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.
- On Coumadin/ warfarin.
- Unable to participate for the required duration of the study.
Key Trial Info
Start Date :
September 13 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT06515184
Start Date
September 13 2024
End Date
December 1 2027
Last Update
November 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC San Diego
La Jolla, California, United States, 92093